Cumberland Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application

Freenome, a privately held biotech company, announced today it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT

Opentrons, a leader in lab automation, announces the launch of its Opentrons Flex robot, a new generation of affordable and easy-to-program liquid-handling lab robots designed to level the playing

Asieris Pharmaceuticals , a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection

Xscientia plc today announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug

Juno Pharmaceuticals Canada a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories one of Canada’s largest domestic specialty

Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA®

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe